Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Arcadia Biosciences (RKDA) EBT (2016 - 2025)

Arcadia Biosciences' EBT history spans 12 years, with the latest figure at -$1.4 million for Q4 2025.

  • For Q4 2025, EBT rose 65.87% year-over-year to -$1.4 million; the TTM value through Dec 2025 reached -$2.5 million, up 49.53%, while the annual FY2025 figure was -$2.3 million, 45.9% up from the prior year.
  • EBT reached -$1.4 million in Q4 2025 per RKDA's latest filing, down from -$1.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $3.2 million in Q2 2023 to a low of -$9.6 million in Q4 2021.
  • Average EBT over 5 years is -$2.1 million, with a median of -$1.6 million recorded in 2021.
  • Peak YoY movement for EBT: surged 183.12% in 2023, then crashed 805.39% in 2024.
  • A 5-year view of EBT shows it stood at -$9.6 million in 2021, then surged by 66.85% to -$3.2 million in 2022, then soared by 85.95% to -$445000.0 in 2023, then plummeted by 805.39% to -$4.0 million in 2024, then skyrocketed by 65.87% to -$1.4 million in 2025.
  • Per Business Quant, the three most recent readings for RKDA's EBT are -$1.4 million (Q4 2025), -$1.2 million (Q3 2025), and -$501000.0 (Q2 2025).